Multiple Sclerosis

New Orleans, LA—Patients with multiple sclerosis (MS) often spend a lifetime using disease-modifying therapy (DMT). Some experts are now wondering whether some of these patients can discontinue treatment without increasing the risk for disease relapse.
New Orleans, LA— The oral investigational agent ozanimod, which is from the same drug class as fingolimod (Gilenya), may be as effective as fingolimod, with fewer safety concerns, for the treatment of patients with relapsing multiple sclerosis (MS), reported Brett E. Skolnick, PhD, Receptos, San Diego, CA, at the 2017 Consortium of Multiple Sclerosis Centers annual meeting. Dr Skolnick stepped in for the lead investigator Giancarlo Comi, MD, Vita-Salute San Raffaele University, Neurology, Milan, Italy, who was unable to attend the meeting.
Orlando, FL—A growing body of evidence supports vitamin D as a dietary factor associated with multiple sclerosis (MS). The question remains, however, whether low serum levels of vitamin D may predispose patients to MS, or whether low levels are a part of the disease, and whether supplementation is really protective. Regardless, the data are suggestive enough to make vitamin D supplementation part of MS management, according to Ellen Mowry, MD, Associate Professor of Neurology, Johns Hopkins University, Baltimore, MD, who discussed the topic at the 2017 Americas Committee for Treatment and Research in Multiple Sclerosis meeting.
Despite improvements in radiographic diagnostic techniques, including magnetic resonance imaging (MRI), the misdiagnosis of multiple sclerosis (MS) is a common problem that can lead to treatment-related and psychosocial morbidity.
A recent study investigated the effects of alemtuzumab (Lemtrada) on disability measures in patients with Multiple Sclerosis (MS).
The past 2 decades have seen significant improvements in disease-modifying therapies (DMTs) for multiple sclerosis (MS), and with them a surge in prices in the cost of therapy with sales more than doubling just in the past few years. As a result, there has been a significant rise in the cost of care for patients with MS.
Findings from an ongoing, phase 3 clinical trial involving patients with relapsing-remitting multiple sclerosis (MS) reveal that hematopoietic stem-cell transplantation (HSCT) may be a feasible treatment option for reversing disability associated with MS.

Multiple sclerosis (MS) is the leading cause of irreversible neurologic disability in young women in the United States, and the second leading cause of neurologic disability in young men. In a series of debates at the 2016 American Academy of Neurology annual meeting, expert physicians addressed current and controversial issues in neuroscience, including the early aggressive treatment of patients with MS.

In a phase 3, randomized clinical trial, natalizumab (Tysabri) failed to slow the progression of ambulatory disability unrelated to relapses (primary end point) in patients with secondary progressive multiple sclerosis (MS). Although patients who received nataliz­umab were less likely to have progression of ambulatory disability than those receiving placebo, the difference was not significant, according to the results presented at the 2016 American Academy of Neurology annual meeting.

The monoclonal antibody ocreliz­umab was recently granted a breakthrough therapy designation by the FDA for the treatment of patients with primary progressive multiple sclerosis (PPMS).
Page 1 of 3
Results 1 - 10 of 27
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology